This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Ticker(s): VERV, NVSWho's the expert?
Institution: CMCP
- Board certified cardiologist in practice for 34 years specializing in cardiology and internal medicine.
- manages treatment for 14 patients with transthyretin amyloidosis (ATTR-CM)
- familiar with the results from the APOLLO-B Phase 3 Study of Patisiran
Interview Goalto discuss the current standard of care and the potential of VERVE-101 from Verve Therapeutics for the treatment of heterozygous familial hypercholesterolemia.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
